Locoregional treatment in oligometastatic breast cancer: A case report and review of treatment approaches in the era of cyclin inhibitors

Metastatic breast cancer is considered incurable. Data regarding how patients with oligometastatic breast cancer might best be treated is limited, with questions concerning the role of locoregional treatment, inclusive of surgery and radiotherapy, and local treatment to the metastatic site. Here we present a case of a 42-year-old woman with oligometastatic HR+/HER2- breast cancer, who achieved a complete radiological response for the metastatic site, after receiving ribociclib and undergoing breast surgery. We review the current evidence for locoregional treatment, and discuss the role of cyclin inhibitors in systemic treatment.